CJC-1295 Research Peptide (RUO)

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), built on the GHRH(1-29) backbone with four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27) intended to resist enzymatic degradation. The material supplied is the form known as CJC-1295 without DAC (also called Modified GRF 1-29): a 29-residue peptide amide and does not carry the maleimidopropionyl 'drug affinity complex' (DAC) albumin-binding modification, so it is shorter-acting than the separate DAC-conjugated variant. CAS numbers for the two forms are used inconsistently across databases: PubChem attaches 863288-34-0 to the 29-residue structure but lists it as a deprecated number for CJC-1295 with DAC (446262-90-4), so the sequence, formula and observed mass are the reliable identifiers. Mechanistically, GHRH analogues act on GHRH receptors of the anterior pituitary to influence growth-hormone signalling; this is described here as a factual mechanism, not a therapeutic claim.

Chemically, CJC-1295 (CAS 863288-34-0, molecular formula C152H252N44O42, ~3367.9 g/mol) is a 29-amino-acid modified GHRH(1-29) analogue typically encountered as a lyophilised powder. CJC-1295 is not approved by the FDA, EMA or other major regulators for therapeutic use; clinical development of the compound was discontinued and it is prohibited under the World Anti-Doping Agency code.

How CJC-1295 Is Produced & Characterised

CJC-1295 is a synthetically demanding peptide: the 29-mer length, the D-amino-acid substitution at position 2 and multiple non-native residues all create opportunities for deletion sequences, diastereomers and epimerisation that must be tightly controlled. Modified GHRH analogues of this type are generally prepared by optimised Fmoc solid-phase peptide synthesis (SPPS), then purified on preparative dynamic axial compression (DAC) HPLC columns to isolate the target sequence sharply from closely related impurities, and lyophilised to a stable, uniform powder.

Analytical characterisation for peptides of this complexity typically combines UPLC/HPLC purity determination with LC-MS to confirm the intended sequence and resolve minor structural variants, alongside measurement of water content, acetate/counter-ion content, residual solvents and peptide content.

Regulatory Status & Context

CJC-1295 is not approved by the FDA, EMA or other major regulators for therapeutic use. Its clinical development was discontinued, and it has no marketing authorisation as a finished medicinal product. The compound is prohibited under the World Anti-Doping Agency (WADA) code.

Because CJC-1295 has no approved therapeutic indication, it is encountered only in research and reference-standard contexts. No efficacy or therapeutic-benefit claims are associated with the molecule.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade CJC-1295 to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to CJC-1295 in their country.